Terapeutic potential of different phosphodiesterase inhibitors in a model of acute lung injury Source: Eur Respir J 2004; 24: Suppl. 48, 264s Year: 2004
Effects of phosphodiesterase inhibitors on the lung functions in a saline lavage-induced model of acute lung injury Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Effect of phosphodiesterase-4 inhibitor on the inflammation, oxidative damage and apoptosis in a saline lavage-induced model of acute lung injury Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury Source: Eur Respir J 2008; 31: 633-644 Year: 2008
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
The therapeutic potential of a new phosphodiesterase inhibitor in acute respiratory distress syndrome Source: Eur Respir J 2002; 20: Suppl. 38, 36s Year: 2002
ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin Source: Eur Respir J 2008; 31: 363-371 Year: 2008
Antithrombin plus alpha–1 protease inhibitor does not affect pulmonary inflammation and coagulation in a ‘double-hit’ lung injury model Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018
Hsp90 binding inhibitors improve survival in a murine model of sepsis induced acute lung injury Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS) Year: 2006
Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Treatment with proteinase inhibitor, BbCI, modulates inflammatory response, mechanic alterations, and remodeling on elastase-induced emphysema in mice Source: Annual Congress 2012 - The many roads to lung injury Year: 2012
Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
Gabexate mesilate attenuates ischemia-reperfusion injury of lung grafts via the inhibition of neutrophil activation Source: Annual Congress 2005 - Recent advances in graft dysfunction after lung transplantation Year: 2005
TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells Source: Virtual Congress 2021 – Emerging respiratory diseases: state-of-the-art studies of SARS-CoV-2 infection Year: 2021
Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia Source: Eur Respir J 2009; 33: 861-870 Year: 2009
Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001